Dr. Nikhil C. Munshi, MD, is currently Professor of Medicine at the Harvard Medical School, as well as director of Basic and Correlative Science. He is also an attending physician at the Brigham and Women’s Hospital at the Boston VA Healthcare system, and the Associate Director of the Jerome Lipper Multiple Myeloma Center at the Dana Farber Cancer Institute.
He is a world recognized leader in translational research, and has published landmark findings with regards to the molecular mechanisms driving genomic instability in Multiple Myeloma (MM). His research team addresses a wide scope of subjects, including those aimed at improving diagnosis and prognosis, as well as developing novel immunotherapies. He has a strong focus on ‘bench to bedside’ development, with many successful collaborations leading to present day treatments.
Dr. Munshi received his medical degree from the Maharaja Sayjirao University, India, in 1984, then completed his postgraduate training in Internal Medicine at SSG Hospital in Baroda. He then took up a Research Fellowship in Medical Oncology at the Johns Hopkins Oncology Center in Baltimore, Maryland, before moving to the Indiana University Medical Center in 1990 to take up a clinical fellowship in hematology/oncology. Dr. Munshi moved to Harvard in 2001 to join the Dana-Farber Cancer Institute.
Dr. Munshi has published more than 300 manuscripts or book chapters in peer-reviewed journals and holds a number of positions on influential committees. He was the founding member of the International Myeloma Society (IMS), and is currently IMS Vice President. He is also co-chair of the National Steering Committeeon Myeloma (National Cancer Institute), which influences the activities of all US Co-Operative Oncology Groups, as well as a member of the National Cancer Institute Clinical Trials and Translational Research Advisory Committee. He has received a number of accolades in recognition of his work, including a Leukemia Society of America Scholar in Translational Research award, the lifetime achievement award from the Association of VA Hematologist and Oncologist, and in 2013 he received the Waldenström’s Award for his lifetime achievement and contributions to myeloma research.